Allogene Therapeutics (ALLO) Interest & Investment Income (2021 - 2026)

Allogene Therapeutics has disclosed Interest & Investment Income across 6 years of filings, most recently posting $3.6 million for Q1 2026.

• Interest & Investment Income for Q1 2026 came in at $3.6 million, down 35.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.3 million (down 14.28% YoY), and the FY2025 annual result was $19.3 million, down 4.29% from the prior year.
• Interest & Investment Income came in at $3.6 million for Q1 2026 at Allogene Therapeutics, down from $3.7 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $6.7 million in Q3 2024 to a low of $315000.0 in Q2 2022.
• The 5-year median for Interest & Investment Income is $3.8 million (2023), against an average of $3.9 million.
• Across the five-year window, Interest & Investment Income soared 1382.26% in 2022 and slumped 51.68% in 2024, its largest moves.
• Allogene Therapeutics' Interest & Investment Income stood at $2.8 million in 2022, then jumped by 127.24% to $6.3 million in 2023, then plunged by 51.68% to $3.0 million in 2024, then grew by 20.91% to $3.7 million in 2025, then declined by 2.38% to $3.6 million in 2026.
• The last three Interest & Investment Income figures came in at $3.6 million (Q1 2026), $3.7 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.